[A23-45] Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V
Last updated 17.11.2023
Project no.:
A23-45
Commission:
Commission awarded on 15.05.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after ≥ 2 lines of systemic therapy
- Patients who are eligible for high-dose therapy: added benefit not proven
- Patients who are not eligible for high-dose therapy: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| G23-25 | Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45 | Commission completed |
Federal Joint Committee (G-BA)
2023-11-16 A G-BA decision was published.